These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

499 related items for PubMed ID: 17573581

  • 1. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial.
    Rossi J, Bayram M, Udelson JE, Lloyd-Jones D, Adams KF, Oconnor CM, Stough WG, Ouyang J, Shin DD, Orlandi C, Gheorghiade M.
    Acute Card Care; 2007; 9(2):82-6. PubMed ID: 17573581
    [Abstract] [Full Text] [Related]

  • 2. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
    Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C, Tolvaptan Investigators.
    Circulation; 2003 Jun 03; 107(21):2690-6. PubMed ID: 12742979
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study.
    Klein L, O'Connor CM, Leimberger JD, Gattis-Stough W, Piña IL, Felker GM, Adams KF, Califf RM, Gheorghiade M, OPTIME-CHF Investigators.
    Circulation; 2005 May 17; 111(19):2454-60. PubMed ID: 15867182
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry.
    Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, O'Connor CM, She L, Yancy CW, Young J, Fonarow GC, OPTIMIZE-HF Investigators and Coordinators.
    Eur Heart J; 2007 Apr 17; 28(8):980-8. PubMed ID: 17309900
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
    Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C, SALT Investigators.
    N Engl J Med; 2006 Nov 16; 355(20):2099-112. PubMed ID: 17105757
    [Abstract] [Full Text] [Related]

  • 10. EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan.
    Cavalcante JL, Khan S, Gheorghiade M.
    Expert Rev Cardiovasc Ther; 2008 Nov 16; 6(10):1331-8. PubMed ID: 19018685
    [Abstract] [Full Text] [Related]

  • 11. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C, Hutchinson DJ.
    Clin Ther; 2010 Jun 16; 32(6):1015-32. PubMed ID: 20637957
    [Abstract] [Full Text] [Related]

  • 12. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program.
    Blair JE, Zannad F, Konstam MA, Cook T, Traver B, Burnett JC, Grinfeld L, Krasa H, Maggioni AP, Orlandi C, Swedberg K, Udelson JE, Zimmer C, Gheorghiade M, EVEREST Investigators.
    J Am Coll Cardiol; 2008 Nov 11; 52(20):1640-8. PubMed ID: 18992654
    [Abstract] [Full Text] [Related]

  • 13. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF).
    Klein L, Massie BM, Leimberger JD, O'Connor CM, Piña IL, Adams KF, Califf RM, Gheorghiade M, OPTIME-CHF Investigators.
    Circ Heart Fail; 2008 May 11; 1(1):25-33. PubMed ID: 19808267
    [Abstract] [Full Text] [Related]

  • 14. Comparison of 60-day mortality in hospitalized heart failure patients with versus without hypothermia.
    Payvar S, Orlandi C, Stough WG, Elkayam U, Ouyang J, Casscells SW, Gheorghiade M, Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators.
    Am J Cardiol; 2006 Dec 01; 98(11):1485-8. PubMed ID: 17126655
    [Abstract] [Full Text] [Related]

  • 15. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T.
    Cardiovasc Drug Rev; 2007 Dec 01; 25(1):1-13. PubMed ID: 17445084
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
    Mao ZL, Stalker D, Keirns J.
    Clin Ther; 2009 Jul 01; 31(7):1542-50. PubMed ID: 19695403
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.
    Hauptman PJ, Burnett J, Gheorghiade M, Grinfeld L, Konstam MA, Kostic D, Krasa HB, Maggioni A, Ouyang J, Swedberg K, Zannad F, Zimmer C, Udelson JE, Everest Investigators.
    J Card Fail; 2013 Jun 01; 19(6):390-7. PubMed ID: 23743487
    [Abstract] [Full Text] [Related]

  • 19. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.
    Wong F, Blei AT, Blendis LM, Thuluvath PJ.
    Hepatology; 2003 Jan 01; 37(1):182-91. PubMed ID: 12500203
    [Abstract] [Full Text] [Related]

  • 20. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
    Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N, Conivaptan Study Group.
    Am J Nephrol; 2007 Jan 01; 27(5):447-57. PubMed ID: 17664863
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.